Clinical Trial Update: Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating binimetinib in combination with hydroxychloroquine for advanced KRAS-mutant non-small cell lung cancer has completed. Results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Binimetinib (binimetinib)
• Hydroxychloroquine (hydroxychloroquine)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Non-Small Cell Lung Cancer, KRAS Mutation-Related Tumors | Phase 2 | Status: COMPLETED | Results posted: 2025-04-01